Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03734692
Recruitment Status : Recruiting
First Posted : November 8, 2018
Last Update Posted : December 3, 2019
AIM ImmunoTech Inc.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Robert Edwards, University of Pittsburgh

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 20, 2021
Estimated Study Completion Date : November 20, 2023